Recent studies implicated that long noncoding RNAs (lncRNAs) may play a role in the progression and development of acute lymphoblastic leukemia, however, this role is not yet clear. In order to unravel the role of lncRNAs associated with Bcell precursor Acute Lymphoblastic Leukemia (BCPALL) subtypes, we performed transcriptome sequencing and DNA methylation array across 82 BCPALL samples from three molecular subtypes (DUX4, Phlike, and Near Haploid or High Hyperdiploidy). Unsupervised clustering of BCPALL samples on the basis of their lncRNAs on transcriptome and DNA methylation profiles revealed robust clusters separating three molecular subtypes. Using extensive computational analysis, we developed a comprehensive catalog of 1235 aberrantly dysregulated BCPALL subtypespecific lncRNAs with altered expression and methylation patterns from three subtypes of BCPALL. By analyzing the coexpression of subtypespecific lncRNAs and proteincoding genes, we inferred key molecular processes in BCPALL subtypes. A strong correlation was identified between the DUX4 specific lncRNAs and activation of TGF and Hippo signaling pathways. Similarly, Phlike specific lncRNAs were β correlated with genes involved in activation of PI3KAKT, mTOR, and JAKSTAT signaling pathways. Interestingly, the relapsespecific differentially expressed lncRNAs correlated with the activation of metabolic and signaling pathways. Finally, we showed a set of epigenetically altered lncRNAs facilitating the expression of tumor genes located at their cis location. Overall, our study provides a comprehensive set of novel subtype and relapse specific lncRNAs in BCPALL. Our findings suggest a wide range of molecular pathways are associated with lncRNAs in BCPALL subtypes and provide a foundation for functional investigations that could lead to new therapeutic approaches.
INTRODUCTION
Bcell Precursor Acute Lymphoblastic Leukemia (BCPALL) is the most prevalent disease in children and affects also adults. Despite improvements in treatment regimens such as chemotherapy and allogeneic hematopoietic stem cell transplantation, the prognosis remains poor for patients in highrisk groups and at relapse (1) . Various risk subtypes have been established based on the cytogenetic analysis and molecular genetics studies. These subtypes are classified based on the presence of high hyperdiploidy (5165 chromosomes) (2) , hypodiploidy (less than 44 chromosomes)(3) and fusion genes (for example BCRABL, ETV6RUNX, MLL, etc) (4) . About 7080% of both adults and pediatric cases of BCPALL constitute these subtypes, although the frequency may differ (5) . development and progression of leukemia (11) and thus constitute as new biomarkers and potential targets for novel therapies (12) .
LncRNAs are arbitrarily defined as transcripts longer than 200 base pairs and lacking an extended proteincoding open reading frame (ORF). It has become apparent that lncRNAs are frequently spliced and polyadenylated and are mainly transcribed by RNA polymerase II (13) . LncRNAs expression has been reported as highly tissuespecific even though the expression abundance is generally lower compared to proteincoding genes (14) . The expression specificity has been extended to a wide variety of physiological and pathological mechanisms like cancer development and Pluripotency (15) . LncRNAs can act either proximally (in the cis region) or distally (in the trans region) for the transcriptional regulation of proteincoding genes (16) . Like proteins, various lncRNAs are attributed to oncogenic or tumorsuppressive (17) activities exerting various cellular functions (18) . In addition, lncRNAs regulate gene expression at the epigenetic (19) and posttranscription (20) levels. Genomewide association studies in cancer have disclosed that 80% of cancer associated singlenucleotide polymorphisms (SNPs) are in noncoding regions (21) , including lncRNAs, suggesting that a significant portion of the genetic etiology of cancer can be related to lncRNAs (22) . Moreover, lncRNAs are reported to be useful for disease prognosis, exemplified by the lncRNA HOTAIR (HOX transcript antisense RNA), which is upregulated in acute myeloid leukemia (AML) patients (23). So far, the majority of studies explored the role of single lncRNAs in leukemia including AML (24) , chronic lymphocytic leukemia (CLL) (25) and pediatric ALL (26) . Yet a comprehensive genomic and epigenetic delineation of lncRNAs deregulations in BCPALL subtypes, and their molecular and functional insights are lacking.
In the present study, we explored lncRNA landscapes in DUX4, Phlike, and NHHeH BCP ALL subtypes and extracted novel biological and functional insights of BCPALL subtype specific lncRNAs and their epigenetic activity. On the basis of RNAseq transcriptional and DNA methylation survey of lncRNAs, we have determined 1235 subtypespecific, relapse specific markers and epigenetically altered lncRNAs and demonstrated their relevance in BCPALL subtype classification. From our indepth analyses, we have inferred the potential functions of subtypespecific lncRNAs. Overall, this work provides a most comprehensive and integrative resource which highlights the impact of lncRNAs on relevant pathways that are dysregulated in the molecular subgroups of BCPALL and may provide new approaches for prognosis and treatment.
RESULTS

Unique lncRNAs expression profiles characterize BCP-ALL subtypes
To identify BCPALL subtypespecific lncRNAs, we analysed transcriptome profiles from paired initial diagnosis (ID) and relapse (REL) samples of 26 pediatric and 22 adult BCP ALL patients lacking known chromosomal translocations like BCRABL. Based on DNA mutations and chromosomal translocations combined with RNA expression and DNA methylation profiles the samples were classified into different molecular subtypes (Table   S1 ), namely DUX4 (n = 23), Phlike (n = 21), Near Haploid or High Hyperdiploid (NH HeH) (n = 16), and lowhypodiploid (LH) (n = 6) and others (n = 18).
When the distribution of lncRNAs gene expression levels across all BCPALL samples was compared with that of proteincoding genes, the former generally showed lower expression levels than the latter (27) (Fig S1A, Table S1 ). The principal component analysis (PCA) on the expression (FPKM value) of 13,860 GENCODE lncRNAs revealed three major BCPALL subtypes, DUX4, Phlike and NHHeH with a distinct separation ( Fig 1A) . This observation is in concordance to the predefined molecular classification. In particular, samples of the DUX4 subtype showed robust separation compared to the remaining samples implying a subtypespecific lncRNAs signatures.
To unveil differentially expressed (DE) lncRNAs across these three major molecular subtypes, we performed DE analysis between subtypes. We obtained 1235 significant DE subtypespecific lncRNAs (Pvalue <= 0.01 and absolute Fold change >= + 1.5) defining signatures of three subtypes ( Fig 1B, Fig S2AC, Table S1 ). Of these, 24 lncRNAs were commonly detected in all 3 BCPALL subtypes ( Fig 1C) , about 523 (Hypergeometric Pvalue Table S1 ) (28) . The remaining 46% (n = 713) of BCPALL subtype specific DE lncRNAs were novel and specific to our subtypes. Out of the overlapped DE lncRNAs (n = 523), 23 (Table S1 ) were crossvalidated in independent cohorts from lnc2cancer (29) database and found to be enriched for oncogenic class of lncRNAs. For example, oncogenic lncRNAs PVT1 (30) and GAS5 (31) are differentially upregulated in the DUX4 subgroup, and CRNDE (32) is DE in Phlike subgroup. Together, subtypespecific lncRNAs signatures assigned molecular subgroups of BCPALL.
Identification and inferred functions of lncRNAs associated with molecular subtypes of BCP-ALL
As lncRNAs can function by regulating proteincoding genes in cis and/or trans (33) (34) (35) (36) regions, we performed functional enrichment analyses using guiltbyassociation approach based on the correlation between neighbouring (cis) and distally (trans) located protein coding (PC) genes (within ± 100 kb cis and >± 100 kb window for trans) of the subtype specific lncRNAs (see materials and methods). Expression of both cis and trans PC genes showed a higher tendency towards positive correlation with the expression of the corresponding lncRNAs (Table 1) . in trans) and Phlike (n = 24 in cis and n = 20 in trans) specific DE lncRNAs demonstrated activation of key signalling pathways involved in proliferation, apoptosis, and differentiation in leukemia (Table S2 ). For example, in the cis based analysis, we identified a strong correlation between DUX4 specific lncRNAs and genes involved in the TGFbeta, Hippo, and P53 signalling pathways (Fig 2A, Table S2 ). Whereas, the Phlike specific lncRNAs were correlated with genes involved in JAKSTAT, mTOR, and PIK3AKT signalling pathways ( Fig 2B, Table S2 ). The trans based analysis revealed same vital signalling pathways in DUX4 subtype ( Fig S3AB, Table S2 ), whereas in Phlike subtype we identified additional signalling pathways, including, P53 and mitogenactivated protein kinase (MAPK) pathways ( Fig S3C, Table S2 ). The strongly coexpressed cis PC genes with DE lncRNAs (n = 32) includes oncogenes including, IL2RA (37), TGFB2 (38) , and CDK6 (39) activated in signalling pathways from DUX4 and Phlike subgroups ( Fig S4AD, Table 23 ). However, there were no significant pathways identified within NHHeH subtype. The subtypespecific cis and trans acting lncRNAs which are upregulated and correlated with genes involved in signalling pathways from DUX4 and Phlike subtypes were hinting their gene expression regulatory activity.
We next related the functions of DUX4 and Phlike specific DE lncRNAs obtained from cis based analysis to those functions identified with DE PC genes. We observed an overlap of 100% (n = 18, Table S2 ) of pathways from the DUX4 subtype between lncRNAs based and PC based functional enrichment analysis ( Fig 2C) . Whereas, in Phlike subtype, we identified 60% (9 out of 15) same pathways between DE PC based and DE lncRNAs based functional enrichment analysis (Table S2 and Fig 2D) . However, we identified Phlike specific lncRNAs to be more strongly correlated with genes involved in key signalling pathways than Phlike specific proteincoding genes. For example, we identified mTOR and PI3KAKT exclusively in the Phlike specific lncRNAs based analysis. Together, our analyses highlight important functions of BCPALL subtypespecific lncRNAs whose expression correlates tightly with that of cancerrelated oncogenes.
Relapse-specific lncRNAs driving BCP-ALL progression
To gain insights into the possible role of lncRNAs driving BCPALL progression, we investigated dysregulation of lncRNAs at relapse. For each molecular BCPALL subtype, we (Table S3 ) emerged as significantly DE (absolute Fold change >= +1.5;
Pvalue <= 0.01) between ID and REL from the three subtypes. Around 20% (n = 186) of those DE lncRNAs were upregulated and 80% were downregulated at relapse. The hierarchical clustering on relapsespecific lncRNAs within each subtype (DUX4, Phlike, NH HeH) identified clear separation between ID and REL ( Fig 3AC) . We observed 19% (183) relapsespecific lncRNAs identified here overlapped with subtypespecific lncRNAs ( Fig 3E) .
The putative molecular functions of relapsespecific lncRNAs were identified using the previously mentioned guiltbyassociation approach. Relapsespecific lncRNAs within Ph like and NHHeH subtypes did not show any significant correlation with activation of pathways. In contrast, in the DUX4 subtype, we identified 56% (n = 321) relapsespecific lncRNAs correlated with cis PC genes (Table S3 ). These strongly correlated relapsespecific lncRNAs showed activation of PC genes involved in vital signalling pathways and metabolic pathways, including NFkappa Bsignalling pathway, cell adhesions molecule (CAMS) and metabolic pathways (number of genes involved >= 3 and Pvalue <= 0.05) ( Fig 3D, Table   S3 ). These results indicate that relapsespecific markers from DUX4 subtype may be functionally engaged in metabolic and signalling pathways.
Subtype specific BCP-ALL lncRNAs show epigenetic alterations
For the analysis of the methylation status of loci located at the lncRNAs genomic position in the BCPALL subtypes, we used DNA methylation array data (collected from Illumina 450k methylation array) from the same patients (n = 46) including matched diagnosis (ID) and relapse (REL) samples (n = 82). The distribution of DNA methylation levels of CpG sites (n = 60,021, Table S4 ) associated with 7,160 lncRNAs was compared with CpG sites associated with PC genes across all BCPALL samples. Unlike the expression levels, the distribution of DNA methylation (hypomethylation or hypermethylation) between lncRNAs and PC genes were similar ( Fig S1B) . Given the robust separation of BCPALL subtypes on DNA methylation profile of CpGs associated with lncRNAs on the PCA analysis ( Fig 4A) , we next studied the differential hypomethylated (methylation difference value < 0; Pvalue <= 0.05) and hypermethylated (methylation difference value > 0.2; Pvalue <= 0.05) CpGs associated with lncRNAs in each subtype (see materials and method). The hierarchical clustering of differentially methylated (DM) lncRNAs showed distinct methylation patterns of each subtype, concordant with the DE lncRNAs signature ( Fig 4BD , Table S4 ). In the DUX4 and NHHeH subtypes the number of hypomethylated lncRNAs (differential methylation value < 0, Pvalue <= 0.05) were higher compared to the number of hypermethylated lncRNAs. We classified the DM lncRNAs based on their genomic regions as gene body methylated and promoterTSS methylated. In the promoter methylated lncRNAs we identified the same trend with high degree of hypomethylated and lower number hypermethylated lncRNAs in DUX4 and NHHeH subtypes. However, the Ph like subtype has shown a higher degree of hypermethylated DM lncRNAs than hypo methylated DM lncRNAs. The list of subtypespecific DM lncRNAs from three subtypes contained previously defined epigenetically altered lncRNAs from other cancer types, for example, we observed the oncogenic lncRNAs LINC00312 (40), PVT1, and TCL6 (41), which are differentially methylated in at least one of the three subtypes. Together, this data illustrates that epigenetically altered lncRNAs within three BCPALL subtypes.
Correlation between differentially expressed and differentially methylated lncRNAs
In order to define whether the subtypespecific promoter methylation impacts on the expression level, we compared the promoterTSS differential CpG methylated lncRNAs (n = 227) with its differential expression signature. We observed 44 lncRNAs with differential methylation pattern in their promoter region with differential expression pattern at RNA level. Out these, lncRNAs harboring significant hypomethylation and hypermethylation pattern (Pearson correlation, 2tailed Pvalue <= 0.05) at the promoter region accounted for 23 (Table 4 ) lncRNAs across the three BCPALL subtypes. The lncRNAs are promoter differentially methylated and differentially expressed in their Fig 5B and 5C ). In the Phlike subtype, we observed 7 lncRNAs with promoter methylation ( Fig 5D) ; interestingly, the same lncRNA R11138M12.1 showed significant hypermethylation at the promoter region and a concordant downregulation in the Phlike subgroup ( Fig 5E) . Besides these novel lncRNAs, we identified lncRNAs previously reported in the context of different cancers from our epigenetically altered (Table 5 ) . The significance is calculated based on Pearson correlation rate and two tailed Pvalue These findings suggest that epigenetic silencing and activation of promoter lncRNAs may be a mechanism that contributes to the dysregulation of expression of lncRNAs. In addition to that, both intronic and intergenic DM lncRNAs associated with strong enhancer and insulator regions can accelerate its expression at the epigenetic level.
Epigenetic alterations of subtypespecific lncRNAs are associated with evelvated expression of tumor genes located at their cis region
We next investigated the relationship between the epigenetic alterations of DM subtype specific lncRNAs (n = 1118) and the aberrant expressions of their cis PC genes. We found 78 proteincoding genes located in their cis region, out of these 33 proteincoding genes have shown a significant upregulated and downregulated expression pattern in their corresponding subtypes (Table 6 ). The table represents hypomethylated and hyper methylated lncRNAs Another important aspect of our study is the identification of relapsespecific dysregulated lncRNAs across three BCPALL subtypes. A closer look into the relapsespecific lncRNAs signature identified lncRNAs previously described as oncogenic: lncRNAs including, RP11
701P16.5 (50) , SLC38A3 (51) , and LINC00312 (40) , which are upregulated in relapsed samples within DUX4 subtype (Table 7 ). The differentially expressed lncRNAs between relapse (REL) and initial diagnosis (ID), from three subtypes, which were previously reported for its disease association, Besides the oncogenic properties, lncRNAs can act as prognostic markers (53) and aid for disease diagnosis and treatment. A subset of our relapsespecific lncRNAs (n = 61, Table   S3 ) is recently identified as prognostic markers in 14 PanCancer data (36) previous studies emphasizing the strengths of the employed guiltbyassociation. For example, lncRNA AC002454.1, which we associated to the PIK3AKT pathway in Phlike subtype, was recently reported to regulate cyclindependent kinase (CDK6) to participate in cell cycle disorder (55) . The CDK6 gene appears to be frequently dysregulated in hematopoietic malignancies (39) and is hence attributed a critical role in tumorigenesis, also shown in ALL driven by mixed lineage leukemia fusion proteins (56). In Phlike subtype, both CDK6 and AC002454.1 are correlated and upregulated specifically in Phlike samples, suggesting they displayed enhancerlike functions. We identified 8 relapsespecific lncRNAs (Table S3 ) associated with metabolic pathways in the DUX4 subtype overlapping with lncRNAs reported (57) and TGFB in DUX4 subtype may indicate their functional relatedness or regulatory relationships. In addition to that, a notable observation was a strong correlation between relapsespecific lncRNAs with genes involved in the activation of metabolic pathways in the DUX4 subtype. We identified 112 relapsespecific lncRNAs coexpressed with 29 (Table S3) PC genes activated in metabolic pathways, including previously reported 8 biomarker lncRNAs. For example, we identified oncogenic lncRNA LUCAT1 reported to be associated with poor prognosis in lung cancer (54) . However, the LUCAT1 has not yet been reported in the BCPALL context. The global coexpression analysis and geneexpression profiling suggest important and previously unappreciated roles of lncRNAs in the BCPALL subtypes.
Our analyses provide important functions of subtypespecific and relapsespecific lncRNA genes whose expression correlates tightly with oncogenic coding genes.
Although we observed that subtypespecific lncRNAs and subtypespecific proteincoding genes were predicted to activate or inhibit the same pathways, some important exclusivity was observed. For instance, the signalling pathways such as the PI3K and mTOR in Phlike subtype was enriched only in the lncRNAs based enrichment analysis, whereas these pathways did not appear to be enriched/dysregulated in the mRNA based analysis. The Additionally, we also demonstrated these lncRNAs might contribute to the regulation of key signalling pathways involved in BCPALL. In summary, our study provides a comprehensive set of dysregulated lncRNAs from BCPALL subtypes derived using different integrative approaches. This can serve as a major resource of BCPALL subtypespecific lncRNAs and their mechanisms of action in detail that might pave the way for the future studies to investigate key biomarkers and potential therapeutic targets in BCPALL subtypes.
Materials and Methods
Patient samples
Patients (n = 46) used in this project were negatively selected for fusion genes detectable 
RNA-seq read alignment and quantitative extraction
The STAR aligner (version 2.4.0.1) (67) (2pass alignment parameters) was used to align pairedend reads to the human genome reference. The human genome reference files used for processing RNAseq samples were the hg19 (GRCh37) genome version for alignment and transcript annotation from GENCODE version 19 (equivalent Ensembl GRCh37). The transcriptome construction and genelevel counts for each sample were obtained using StringTie (68) . The read count information from the files generated by StringTie was extracted using the "prepDE.py" python script provided by the StringTie. We detected 84% of 13,860 lncRNAs (including 23,898 transcripts) annotated by GENCODE (V19) from our samples (FPKM > 0 for multiexon lncRNAs and FPKM > 0 for single exonic lncRNAs)
showing that our sequencing depth was good.
Sample clustering and differential expression analysis for subtype-specific and relapse-specific lncRNAs
We performed PCA using the prcomp R function on 13,860 lncRNAs from RNAseq and 
Functional predictions using guilt-by-association approach
In our study, we used the "guiltbyassociation" functional enrichment analysis using GeneSCF v1.0 (73) . The functional enrichment analysis was performed using the KEGG database with a background of all proteincoding genes from GENCODE v19 (20, 345) . The functional terms were considered significant only if it is enriched with Pvalue <= 0.05.
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